Status and phase
Conditions
Treatments
About
A phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 in monotherapy or in combination in patients with NSCLC, HNSCC, GC/GEJ, ESCC, or other solid tumors and who are treatment naïve or have progressed after receiving prior therapy for advanced/metastatic disease.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Part One: Patients with NSCLC, GC/GEJ, HNSCC, or ESCC who have failed prior standard first-line treatment. Patients must have progressed on or be intolerant to therapies that are known to provide clinical benefit. There is no limit to the number of prior treatment regimens.
Part Two: Patients with NSCLC, HNSCC, other solid tumors and applicable mutations as determined by the investigator.
Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
576 participants in 7 patient groups
Loading...
Central trial contact
Merus Inquiries
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal